سعر ازجوديابيتو 2/30 مجم 20 قرص 2022

Glimepiride 2 mg + pioglitazone 30 mg tablets, 20 tablets; oral antidiabetic combination (Sedico for APIC, Egypt).

• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus already treated with a thiazolidinedione and a sulfonylurea or inadequately controlled on either alonePopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (5% or more): upper respiratory tract infection, accidental injury and combined edema/peripheral edema.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Initiation in patients with established NYHA class III or IV heart failure; known hypersensitivity to pioglitazone, glimepiride or any component; history of allergic reaction to sulfonamide derivatives.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Not for type 1 diabetes or diabetic ketoacidosis (limitation of use).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning - congestive heart failure: thiazolidinediones cause or exacerbate heart failure; observe for rapid weight gain, dyspnea and edema; not recommended in symptomatic heart failure.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypoglycemia (glimepiride; higher risk with insulin or other secretagogues, elderly, renal impairment); serious hypersensitivity reactions; possible increased cardiovascular mortality with sulfonylureas.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hepatic effects (postmarketing hepatic failure with pioglitazone), urinary bladder tumors (avoid in active bladder cancer), dose-related edema, increased fracture incidence in women, hemolytic anemia in G6PD deficiency, and macular edema.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP2C8 inhibitors (e.g. gemfibrozil)Increase pioglitazone exposure; use individual components (maximum pioglitazone 15 mg daily).DailyMed (U.S. National Library of Medicine)
• CYP2C8 inducers (e.g. rifampin)May decrease pioglitazone exposure; monitor glycemic control.DailyMed (U.S. National Library of Medicine)
• TopiramateMay decrease pioglitazone concentrations; monitor glycemic control.DailyMed (U.S. National Library of Medicine)

• Limited data with pioglitazone/glimepiride or its components in pregnancy are insufficient to determine a drug-associated risk; poorly controlled diabetes carries maternal and fetal risks.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No information on the presence of pioglitazone or glimepiride in human milk; weigh benefits of breastfeeding against the mother's need and possible infant effects (monitor breastfed infants for hypoglycemia).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Glimepiride: Sulfonylurea that lowers blood glucose mainly by stimulating insulin release from functioning pancreatic beta cells (US label).
• Pioglitazone: Thiazolidinedione that depends on the presence of insulin; decreases insulin resistance in the periphery and liver via PPAR-gamma agonism (US Duetact label).